Jaguar Health Regains Nasdaq Compliance and Achieves 816% Q1 Revenue Growth
JAGX•Jaguar Health regained compliance with the Nasdaq bid price rule on May 26, ensuring its shares remain listed and traded. In Q1 2026, revenue jumped 816% year-over-year and 527% sequentially on a Future Pak out-license for Mytesi and Canalevia-CA1, while a pivotal-stage crofelemer oral solution targets an NDA in mid-2027.
1. Regained Nasdaq Compliance
On May 26, Jaguar Health received formal notice that it met the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), restoring compliance and securing continued listing and trading of its securities.
2. Q1 2026 Revenue Surge
The company reported net revenue growth of 816% year-over-year and 527% quarter-over-quarter in Q1 2026, driven primarily by a US out-license agreement executed in January with Future Pak for Mytesi and Canalevia-CA1.
3. Development Pipeline and Outlook
Jaguar Health is advancing a pivotal-stage powder-for-oral-solution formulation of crofelemer for rare intestinal failure indications, targeting an NDA filing in mid-2027 and actively seeking a development and commercialization partner for the program.
